We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of serum HER2-ECD levels in patients with gastric cancer.
- Authors
Oyama, Katsunobu; Fushida, Sachio; Tsukada, Tomoya; Kinoshita, Jun; Watanabe, Toshifumi; Shoji, Masatoshi; Nakanuma, Shinichi; Okamoto, Koichi; Sakai, Seisho; Makino, Isamu; Nakamura, Keishi; Hayashi, Hironori; Inokuchi, Masafumi; Nakagawara, Hisatoshi; Miyashita, Tomoharu; Tajima, Hidehiro; Takamura, Hiroyuki; Ninomiya, Itasu; Kitagawa, Hirohisa; Fujimura, Takashi
- Abstract
Background: Determination of the human epidermal growth factor receptor 2 (HER2) status of gastric cancer patients is indispensable in clinical practice. However, the clinical value of serum HER2-extracellular domain (ECD) in gastric cancer has not yet been defined. Methods: The serum level of HER2-ECD was measured using the chemiluminescence immunoassay method, and its relationship with tissue HER2 status and clinicopathologic features was examined. Transition of serum HER2-ECD level was examined in patients during chemotherapy to clarify the correlation between changes in the level of HER2-ECD in serum and response to chemotherapy. Results: A total of 150 gastric cancer patients were enrolled in this study; changes in HER2-ECD level were examined in 36 of these patients during chemotherapy. Serum levels of HER2-ECD ranged from 4.8 to 180.0 ng/ml (median 9.2 ng/ml) and were positive (cutoff value 15.2 ng/ml) in ten patients (6.7 %). There was a significant correlation between serum HER2-ECD level and tissue HER2 status ( P < 0.001); however, no correlation with TNM stage was found. Change in serum HER2-ECD level during chemotherapy was significantly correlated with response to chemotherapy in patients with HER2-positive tumor tissue. Conclusions: Serum HER2-ECD is a potential biomarker of gastric cancer and could be used as a diagnostic marker with regard to tissue HER2 status, and also as a monitoring marker in relation to response to chemotherapy.
- Subjects
HER2 gene; STOMACH cancer patients; PHYSICIAN practice patterns; EXTRACELLULAR matrix; CHEMILUMINESCENCE immunoassay; CANCER chemotherapy; TUMOR markers
- Publication
Journal of Gastroenterology, 2015, Vol 50, Issue 1, p41
- ISSN
0944-1174
- Publication type
Article
- DOI
10.1007/s00535-014-0941-3